Literature DB >> 25605842

Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.

Constantine S Mitsiades1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25605842      PMCID： PMC4517049          DOI： 10.1200/JCO.2014.55.5748

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  74 in total

1.  Regulatory role of proteasome in determination of platelet life span.

Authors:  Manasa K Nayak; Paresh P Kulkarni; Debabrata Dash
Journal:  J Biol Chem       Date:  2013-01-17       Impact factor: 5.157

Review 2.  Ubiquitin-proteasome system and hereditary cardiomyopathies.

Authors:  Saskia Schlossarek; Norbert Frey; Lucie Carrier
Journal:  J Mol Cell Cardiol       Date:  2013-12-28       Impact factor: 5.000

3.  Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.

Authors:  Paul G Richardson; Rachid Baz; Michael Wang; Andrzej J Jakubowiak; Jacob P Laubach; R Donald Harvey; Moshe Talpaz; Deborah Berg; Guohui Liu; Jiang Yu; Neeraj Gupta; Alessandra Di Bacco; Ai-Min Hui; Sagar Lonial
Journal:  Blood       Date:  2014-06-11       Impact factor: 22.113

4.  The 19S Deubiquitinase inhibitor b-AP15 is enriched in cells and elicits rapid commitment to cell death.

Authors:  Xin Wang; William Stafford; Magdalena Mazurkiewicz; Mårten Fryknäs; Slavica Brjnic; Xiaonan Zhang; Joachim Gullbo; Rolf Larsson; Elias S J Arnér; Padraig D'Arcy; Stig Linder
Journal:  Mol Pharmacol       Date:  2014-04-08       Impact factor: 4.436

5.  Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

Authors:  Richard I Fisher; Steven H Bernstein; Brad S Kahl; Benjamin Djulbegovic; Michael J Robertson; Sven de Vos; Elliot Epner; Amrita Krishnan; John P Leonard; Sagar Lonial; Edward A Stadtmauer; Owen A O'Connor; Hongliang Shi; Anthony L Boral; André Goy
Journal:  J Clin Oncol       Date:  2006-09-25       Impact factor: 44.544

6.  Autoubiquitination of the 26S proteasome on Rpn13 regulates breakdown of ubiquitin conjugates.

Authors:  Henrike C Besche; Zhe Sha; Nikolay V Kukushkin; Andreas Peth; Eva-Maria Hock; Woong Kim; Steven Gygi; Juan A Gutierrez; Hua Liao; Lawrence Dick; Alfred L Goldberg
Journal:  EMBO J       Date:  2014-05-08       Impact factor: 11.598

7.  Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.

Authors:  Paul G Richardson; David Siegel; Rachid Baz; Susan L Kelley; Nikhil C Munshi; Jacob Laubach; Daniel Sullivan; Melissa Alsina; Robert Schlossman; Irene M Ghobrial; Deborah Doss; Nora Loughney; Laura McBride; Elizabeth Bilotti; Palka Anand; Lisa Nardelli; Sandra Wear; Gail Larkins; Min Chen; Mohamad H Zaki; Christian Jacques; Kenneth C Anderson
Journal:  Blood       Date:  2012-12-14       Impact factor: 22.113

8.  Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.

Authors:  Paul G Richardson; David S Siegel; Ravi Vij; Craig C Hofmeister; Rachid Baz; Sundar Jagannath; Christine Chen; Sagar Lonial; Andrzej Jakubowiak; Nizar Bahlis; Kevin Song; Andrew Belch; Noopur Raje; Chaim Shustik; Suzanne Lentzsch; Martha Lacy; Joseph Mikhael; Jeffrey Matous; David Vesole; Min Chen; Mohamed H Zaki; Christian Jacques; Zhinuan Yu; Kenneth C Anderson
Journal:  Blood       Date:  2014-01-13       Impact factor: 22.113

9.  Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy.

Authors:  J R Berenson; J D Hilger; O Yellin; R Dichmann; D Patel-Donnelly; R V Boccia; A Bessudo; L Stampleman; D Gravenor; S Eshaghian; Y Nassir; R A Swift; R A Vescio
Journal:  Leukemia       Date:  2014-01-16       Impact factor: 11.528

10.  Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.

Authors:  Kyriakos P Papadopoulos; David S Siegel; David H Vesole; Peter Lee; Steven T Rosen; Naseem Zojwalla; Joseph R Holahan; Susan Lee; Zhengping Wang; Ashraf Badros
Journal:  J Clin Oncol       Date:  2014-09-15       Impact factor: 44.544
View more
  6 in total

Review 1.  Cardiovascular Complications Associated with Multiple Myeloma Therapies: Incidence, Pathophysiology, and Management.

Authors:  Vivek G Patel; Robert F Cornell
Journal:  Curr Oncol Rep       Date:  2019-03-05       Impact factor: 5.075

Review 2.  Cardiovascular Complications of Multiple Myeloma Treatment: Evaluation, Management, and Prevention.

Authors:  Dae Hyun Lee; Michael G Fradley
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-03-06

3.  Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide.

Authors:  Ruud Oerlemans; Celia R Berkers; Yehuda G Assaraf; George L Scheffer; Godefridus J Peters; Sue Ellen Verbrugge; Jacqueline Cloos; Jerry Slootstra; Rob H Meloen; Robert H Shoemaker; Ben A C Dijkmans; Rik J Scheper; Huib Ovaa; Gerrit Jansen
Journal:  Invest New Drugs       Date:  2018-02-14       Impact factor: 3.850

4.  Neural precursor cell expressed, developmentally downregulated 8 promotes tumor progression and predicts poor prognosis of patients with bladder cancer.

Authors:  Da-Wei Tian; Zhou-Liang Wu; Li-Ming Jiang; Jie Gao; Chang-Li Wu; Hai-Long Hu
Journal:  Cancer Sci       Date:  2018-12-10       Impact factor: 6.716

5.  Bortezomib-Induced Reversible Cardiomyopathy: Recovered With Guideline-Directed Medical Therapy.

Authors:  Swethika H Sundaravel; Rosalyn I Marar; Muhannad A Abbasi; Muhamed Baljevic; Jeremy R Stone
Journal:  Cureus       Date:  2021-12-09

6.  Proteasome and heat shock protein 70 (HSP70) inhibitors as therapeutic alternative in multiple myeloma.

Authors:  Angela Isabel Pereira Eugênio; Veruska Lia Fook-Alves; Mariana Bleker de Oliveira; Rodrigo Carlini Fernando; Daniela B Zanatta; Bryan Eric Strauss; Maria Regina Regis Silva; Marimélia Aparecida Porcionatto; Gisele Wally Braga Colleoni
Journal:  Oncotarget       Date:  2017-12-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.